Journal profile

Current opinion in allergy and clinical immunology

Publisher: Lippincott Williams & Wilkins
ISSN1528-4050 | 1473-6322 FormatPrint StatusCurrently indexed
Official Website Verify CrossRef

Journal Citation Impact

Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.

Impact Factor
3.35
Citation rate 2.81 437 total citations
h5-index 24 h5 depth signal
Cited share 77.2% 125 of 162
Total citations 437 Citation footprint
Metric signal 2.83 External metric anchor
Self-citation 2.5% 11 self-citations

Citations Trend

Monthly Publications Cadence

Citing Geographic Demographics

United States 235
Italy 191
United Kingdom 86
Spain 57
Germany 46

Citing Fields of Research

Allergies 668
Immunology 117
Ophthalmology 58
Cosmetic Surgery 36
Auto-Inflammatory Disorders 25

Publishing Activity & Reach

Volume, recency, access pattern, and citing-community signals from the journal analytics record.

All-time article footprint 2,349 Articles tracked across the journal lifetime
Indexed publication set 162 125 cited publications
Last 12 months 76 6.9 publications/month
Open access share 19.7% 15 OA publications in the last year
Leading citing country United States 235 citing publications
Leading citing field Allergies 668 citing publications
Latest tracked publication 9 October 2026 10 recent records available

Coverage & Indexing History

MEDLINE
v1n1, Feb. 2001-
PubMed
v1n1, Feb. 2001-
Index medicus
Active Coverage

Research Focus & Classification

Indexed Subjects

Allergies

Broad Categories

Allergy and Immunology Allergies

MeSH Descriptors

Allergy and Immunology Hypersensitivity Immune System Diseases Immunity

Latest Publications

Recent article records with DOI-first linking and condensed abstracts.

01
Open DOI
Mário Morais-Almeida, Catarina Fidalgo Dourado, Ignacio J. Ansotegui
Purpose of review: Allergen immunotherapy (AIT) is the only established disease-modifying treatment for IgE-mediated allergic disease, yet treatment remains largely empirical at the individual-patient level. This review critically examin...
05
Open DOI
Betania Arce, Melanie C. Dispenza
Purpose of review: The recent approval of the Bruton's tyrosine kinase inhibitor (BTKi) remibrutinib for the treatment of chronic spontaneous urticaria opened a new therapeutic class of drugs for the allergy space. This review summarizes...
08
Open DOI
Julijana Asllani, Eleni Anastasiou, Nikolaos G. Papadopoulos
Purpose of review: Allergen immunotherapy (AIT) remains the only disease-modifying treatment for respiratory allergic diseases and the only intervention capable of preventing systemic sting reactions in patients with venom allergy (VA)....
09
DOI 10.1097/aci.0000000000001186

Urine mast cell mediators and anaphylaxis

Open DOI
Dayne Voelker, Thanai Pongdee
Purpose of review: Anaphylaxis is a severe type 1 hypersensitivity reaction which is the result of mast cell degranulation causing multiorgan dysfunction. Currently, the most accepted biomarker measurement for mast cell mediated anaphyla...

Bibliographical & Catalog Notes

Title from cover.

Also issued online.

v.1, no. 1 (Feb. 2001)20020531 Notice published Printed on acid-free paper that meets the full ANSI standard for Permanent Paper